Prostate cancer is one of the most frequently diagnosed cancers in men, and when it is identified at an early stage it is generally a highly manageable disease. For many years, the standard responses were either surgical removal of the entire prostate gland or radiation delivered to a wide area. More recently, tissue-preserving, precisely targeted techniques have gained an established place alongside these options. Robotic HIFU (High-Intensity Focused Ultrasound) belongs to this newer generation of approaches: it aims to destroy cancerous tissue using focused heat energy, without an incision, without needles and without radiation.
A defining feature of this method is its ability to target and ablate the diseased area with millimetre-level precision while sparing, as far as possible, the nerves and muscles that govern urinary control and sexual function. The intention is twofold: to bring the disease under control and, at the same time, to protect the functions that directly shape a man's quality of life. In particular, when the cancer is confined to one defined region of the prostate, this technology makes it possible to treat only the diseased focus rather than sacrificing the whole gland.
This article explains how robotic HIFU works, who may be a suitable candidate, how the procedure is carried out, what recovery involves, and how follow-up is organised afterwards. The aim is to give patients who are considering this treatment — including those weighing up treatment abroad — a realistic, start-to-finish picture of the process.
What Is Robotic HIFU and How Does It Work?
HIFU stands for High-Intensity Focused Ultrasound. In everyday medicine, ultrasound is associated with imaging; here, however, the sound waves are used not to create pictures but to heat and destroy tissue. The principle resembles a magnifying glass concentrating sunlight onto a single point: the HIFU device focuses ultrasound waves onto a very small spot inside the prostate. At that focal point, the temperature rises to roughly 60–90°C within seconds, and the cells there are irreversibly destroyed. Tissue outside the focal point is not affected by this heat, because the energy concentrates only in the tiny targeted volume.
The treatment is delivered through a special probe placed in the rectum (a transrectal probe). This probe both images the prostate in real time and emits the therapeutic ultrasound waves. Because the prostate lies immediately in front of the rectum, this route allows the device to reach the gland at very close range without any incision in the skin — the abdominal wall, muscles and skin are left entirely untouched.
The word "robotic" refers to the computer-controlled, robotic positioning of the energy-emitting element. The physician overlays previously acquired magnetic resonance (MRI) images onto the live ultrasound view, producing a three-dimensional map of the area to be treated. The system then works through this map in millimetre-scale steps, ablating the target zone as a series of tiny adjacent foci. Each pulse destroys a small volume of tissue, and the pulses are placed side by side until the entire planned area has been covered.
A useful way to picture this is as a form of three-dimensional tissue sculpting. The margins of the cancerous region are defined, and the system ablates strictly within those boundaries. Critical structures — the muscles responsible for urinary continence, for example, or the nerve bundles involved in erection — can be deliberately left outside the treatment map. This capacity for selective sparing is a notable strength of the technique from a functional point of view.
Understanding the underlying mechanism helps explain why the method can be so precisely targeted. When focused ultrasound energy reaches tissue, it produces two principal effects. The first is thermal: the sound waves cause molecules to vibrate rapidly, generating heat that irreversibly coagulates proteins and kills cells within the small targeted volume. The second is mechanical, related to the formation and collapse of microscopic bubbles within the tissue. Both effects become significant only at the focal point where the energy converges; just beyond it, the temperature falls off sharply and neighbouring tissue is preserved.
This sharp boundary is central to the safety of the procedure. The rectal wall lies directly behind the prostate, while the urethra and bladder neck sit at its front. Treatment is planned with defined safety margins around these sensitive neighbouring structures, and the tissue is monitored on live imaging throughout the session so that the energy can be confirmed to remain within the intended zone. This continuous real-time verification is one of the key technical features that distinguishes the method from traditional whole-gland treatments.
A brief look at the surrounding anatomy makes the tissue-preserving logic clearer. The prostate is a small gland encircling the urethra; close around it lie the muscles that maintain urinary control, the nerve bundles responsible for erection, and, behind it, the rectum. Conventional wide-field treatments can affect some of these structures, whereas the focused approach of robotic HIFU allows therapy to be confined to the diseased region alone. The functional structures nearby can be kept outside the treatment map and thereby protected. The method's emphasis on quality of life rests largely on this anatomical precision.
How Does Robotic HIFU Differ from Conventional HIFU?
Conventional HIFU systems rely on the same physical principle — heating and destroying tissue with focused ultrasound. In earlier-generation devices, however, treatment planning and energy delivery were more limited. The physician typically worked from the ultrasound image alone, outlined the treatment area manually, and applied the energy pulses with relatively coarse margins. This constrained both targeting accuracy and the ability to spare healthy tissue.
Newer robotic systems with MRI fusion introduce several important differences:
- Image fusion: a previously acquired high-resolution prostate MRI is merged with the live ultrasound view, so that cancerous foci visible on MRI but poorly seen on ultrasound can still be included in the treatment map.
- Robotic positioning: the movement of the energy transducer is computer-controlled, eliminating hand tremor and positioning error and allowing pulses to be placed with millimetre-level regularity.
- Real-time feedback: the system monitors tissue changes during treatment and can adjust the energy dose and focal position accordingly.
- Focal therapy capability: partial (focal) treatments that target only the diseased region, rather than the entire gland, can be performed with greater confidence.
In practical terms, these differences mean that newer robotic systems offer a better chance of covering the cancerous tissue completely while protecting healthy and functionally important structures — the target is struck more accurately, and collateral effects on valuable neighbouring tissue are minimised. Conventional HIFU remains a valid technique, but it may not always provide this degree of precise planning and protection.
Repeatability is another meaningful difference. Because robotic planning records the treatment map, the exact location of previous therapy is clearly documented if reassessment is needed later. This simplifies follow-up and any decision about retreatment.
The practical value of image fusion deserves emphasis. Prostate cancer does not always appear as a distinct mass on ultrasound; many tumour foci can only be identified on multiparametric prostate MRI. With older systems, a focus that was visible on MRI but faint on live ultrasound was difficult to target. Fusion technology superimposes the pre-acquired MRI onto the live ultrasound and marks the precise three-dimensional position of that focus, directing treatment to the region known to harbour disease and avoiding unnecessarily broad ablation.
Newer systems also document the treatment itself: which region received how much energy is recorded. This record serves both to verify the quality of the session and to interpret later surveillance MRI scans correctly, since the previously treated area is known. With conventional methods, this level of detailed documentation was not always possible, which could make later reassessment harder. Robotic, fusion-guided approaches therefore support not only the treatment session itself but the entire follow-up process that comes after it.
Who Is a Suitable Candidate — and Who Is Not?
Robotic HIFU is not an appropriate option for every man with prostate cancer; it is considered in patients who meet specific criteria. The most suitable candidates are men with early- or intermediate-stage disease in which the cancer remains confined to the prostate and has not spread to surrounding tissue or distant organs. A low or intermediate aggressiveness grade and a tumour that can be clearly delineated as a focus on MRI improve the likelihood of a successful outcome.
In general, robotic HIFU may be considered in the following situations:
- Organ-confined, low- or intermediate-risk prostate cancer.
- A cancer that is visible as a distinct focus on MRI and has been confirmed at that site by biopsy.
- Patients who place a high priority on preserving urinary control and sexual function.
- Selected patients with local recurrence after previous radiation therapy to the prostate, as a salvage treatment.
- Patients whose overall health makes major surgery inadvisable, or who prefer not to undergo surgery.
Conversely, there are circumstances in which robotic HIFU is not suitable. In advanced disease — where the cancer has breached the prostate capsule, involved lymph nodes, or spread to distant sites such as bone — this method alone is insufficient, and systemic or more comprehensive treatments are required. In addition, a very large prostate, extensive calcification within the gland, or anatomical conditions that prevent placement of the transrectal probe can make the procedure technically difficult.
The decision on suitability is made by weighing MRI findings, biopsy results, blood tests and the patient's overall health together. The treatment plan is therefore tailored to each individual, balancing the biological behaviour of the cancer against the patient's expectations and way of life.
The tumour's position within the prostate is also a relevant detail. Foci in the anterior part of the gland can sometimes be harder to reach because of their distance from the probe, whereas posterior foci, lying close to the transrectal probe, are generally more accessible. For posterior tumours, however, proximity to the rectal wall must be respected and the safety margin carefully maintained. These fine trade-offs mean that each patient's anatomy is assessed individually; a personalised plan replaces any standard formula.
Realistic expectations are equally important. A patient considering focal therapy should understand that treatment targets only the known diseased focus, and that the remainder of the prostate will be monitored over time for the possible emergence of a new focus. For this reason, robotic HIFU calls for detailed counselling and shared decision-making before treatment. The patient's lifestyle, priorities and capacity to adhere to a follow-up programme all form part of that decision.
How Is the Procedure Performed, and How Long Does It Take?
A short preparation phase precedes the procedure. An enema is usually given to empty the bowel, since a clean rectum is important for image quality and safety at the site where the treatment probe will be placed. Patients taking blood-thinning medication may need to stop it for a period beforehand. The procedure itself is performed under general anaesthesia or spinal anaesthesia (numbing the body from the waist down), so the patient feels no pain.
The patient is positioned on the table, typically on the side or in the lithotomy position with the legs raised. Once anaesthesia has taken effect, a urinary catheter is inserted; it serves both to empty the bladder and to track the position of the urethra during treatment. The treatment probe is then placed in the rectum, where it both images and treats the prostate.
The procedure follows these steps:
- Imaging and mapping: after the probe is positioned, a detailed ultrasound view of the prostate is obtained and fused with the previously acquired MRI. The area to be treated is marked in three dimensions.
- Planning: the boundaries of the target zone, the structures to be spared and the energy settings are defined, including safety margins for sensitive structures such as the urethra and the rectal wall.
- Treatment: the robotic system delivers energy in a series of tiny foci according to the plan. Each pulse lasts a few seconds, and successive pulses sweep across the entire target area.
- Verification: once treatment is complete, the area is re-imaged to assess whether coverage is adequate.
Total procedure time depends on the size of the area being treated. Focal treatments addressing only the diseased region typically take one to two hours, while sessions covering the whole gland or a large part of it may extend to around three hours. Because the patient is under anaesthesia throughout, no pain or discomfort is felt. As there is no surgical incision, there are no stitches, no wound and no open operative site at the end of the procedure.
During the session, the team does more than deliver energy: the tissue's response is monitored continuously. Temperature changes at the focal point and evolving features on the images indicate whether the target zone has been treated sufficiently. Additional pulses can be applied to a specific region if needed, or an area can be deliberately spared for safety. This flexibility means the treatment is not a fixed recipe but a dynamic process adapted to each patient's anatomy and tumour location.
Certain practical points are explained to the patient in advance: that a urinary catheter will be worn for a period after treatment, that slight discolouration of the urine may occur in the first days, and why bowel preparation matters. This briefing helps patients approach the procedure well prepared and respond calmly to the temporary effects that follow. A pre-anaesthesia assessment — reviewing general health, current medications and fitness for anaesthesia — is also a routine part of the preparation.
Outcomes and Clinical Results
Two principal measures are used when evaluating the results of robotic HIFU: control of the cancer and preservation of function. In appropriately selected patients with organ-confined, low- to intermediate-risk disease, the method aims to destroy cancer cells effectively within the treated zone. Success is monitored after the procedure through blood tests, surveillance imaging and, where indicated, biopsies.
One of the most important markers in clinical follow-up is the blood value known as PSA. When treatment has been effective, the PSA level falls markedly over time and settles at a low plateau. A renewed rise in PSA can be the first signal that disease may persist in the treated zone or elsewhere, and prompts further investigation.
Several points stand out in the clinical experience with robotic HIFU:
- In focal treatments, the goal is to destroy the diseased focus while preserving healthy prostate tissue and functional structures — an approach that supports quality of life.
- If disease is not controlled in the treated area, selected patients may still be offered repeat HIFU, radiation therapy or surgery. In other words, HIFU does not close the door on subsequent treatments.
- Results vary from person to person, depending on the initial stage of the cancer, its aggressiveness and the patient's general condition.
Setting realistic expectations matters here. In a suitable patient, robotic HIFU is an option that seeks to balance disease control with preservation of quality of life. No treatment produces the same result in every patient, which is why both the treatment decision and the follow-up plan are managed individually, and why regular check-ups carry so much weight.
It is also worth noting that PSA should not be interpreted in isolation. Because part of the prostate remains in place after HIFU, PSA does not fall to zero; it stabilises at a certain level instead. What matters is the trend of this value over time. A single elevated reading does not necessarily indicate recurrence; a rising trend across consecutive measurements is generally what is considered meaningful. Follow-up therefore combines PSA, surveillance imaging and, when necessary, biopsy.
Another factor influencing clinical outcomes is whether treatment is focal or more extensive. Focal treatment of the diseased area alone tends to preserve quality of life better, while treating most of the gland may provide broader cancer control at the cost of somewhat greater functional impact. This balance is struck separately for each patient, taking into account age, life expectancy and personal priorities in finding the appropriate point between cancer control and functional preservation.
Preservation of Urinary Control and Sexual Function
The two concerns that trouble patients most in prostate cancer treatment are urinary incontinence and loss of sexual function. The reason lies in anatomy: the muscles that maintain urinary control and the nerve bundles responsible for erection sit immediately adjacent to the prostate, and traditional wide-field treatments can damage them. An important potential advantage of robotic HIFU is its ability to confine treatment to the diseased region and thereby protect these critical structures.
With respect to urinary control, robotic HIFU generally presents a favourable profile. Because the procedure involves no incision and the continence muscles can be kept outside the treatment map, most patients experience either no incontinence at all or only mild, temporary leakage. A urinary catheter is worn for a period after treatment; once it is removed, there may be temporary difficulty with urine flow, increased frequency or a burning sensation. These symptoms usually subside over a few weeks as the tissue heals.
For sexual function, the decisive factor is the location of the tumour. The erectile nerves run along the posterolateral surface of the prostate. If the cancer lies away from these nerves, focal treatment can spare them and erectile function can be largely maintained. Where the tumour sits close to the nerves, the degree of preservation varies. A temporary weakening of erections may occur in the early period after the procedure; this generally tends to improve with time and, where needed, with supportive measures.
The main factors influencing functional preservation are:
- The tumour's position within the prostate and its distance from critical structures.
- Whether the treatment is focal or more extensive.
- The patient's urinary and sexual function before treatment.
- The patient's age and overall vascular and nerve health.
Expectations for functional preservation are therefore assessed individually before treatment. The general tendency, owing to the tissue-preserving nature of robotic HIFU, is supportive of quality of life — but the outcome is shaped by the individual factors listed above.
Baseline status deserves particular emphasis. A patient whose erectile function was already reduced before treatment will have different expectations afterwards, whereas a patient with good baseline function and a tumour located away from the nerves has a distinctly better chance of preservation. For this reason, urinary and sexual function are documented in detail before treatment; this record allows any change afterwards to be assessed objectively.
Functional recovery is usually gradual. The temporary swelling and tissue healing that follow the procedure can cause fluctuations in urinary and sexual function during the first weeks, and these generally settle as healing progresses. Where appropriate, measures to support erectile function and pelvic-floor strengthening exercises can contribute to this process. Patient follow-through and regular review help ensure that functional recovery is supported as fully as possible.
Hospital Stay and Recovery
One of the most tangible practical advantages of robotic HIFU compared with open surgery is the speed and comfort of recovery. Since the procedure involves no incision, there is no surgical wound, no stitches and no drain. This shortens the hospital stay and accelerates the return to daily life — a consideration of particular relevance for patients travelling from abroad for treatment.
Most patients can be discharged on the day of the procedure or the following day after an overnight stay for observation, once the anaesthetic has worn off and their condition is stable. Patients usually go home with the urinary catheter still in place, because temporary swelling of the prostate after treatment can obstruct urine flow. The catheter is typically kept for a few days up to one or two weeks to allow the tissue time to settle, and is then removed at a follow-up visit.
During recovery, the following are commonly experienced:
- For a period after catheter removal, more frequent urination, mild burning or a sense of urgency.
- Occasional light blood-tinging of the urine or semen, which usually resolves on its own.
- A mild feeling of fullness or discomfort in the prostate region.
- Some tiredness — though not of the intensity or duration seen after major surgery.
Most patients can return to desk-based and light work within about a week. In the early period, it is advisable to avoid heavy physical exertion, prolonged sitting and activities that put pressure on the area, such as cycling. Drinking plenty of water helps flush the urinary tract and supports healing. Overall, recovery after robotic HIFU is considerably shorter and more comfortable than after open or laparoscopic surgery, which makes the method appealing to patients who wish to resume their normal routine quickly.
Diet and daily habits also play a supportive role. Generous fluid intake keeps the urinary tract working and reduces the likelihood of infection. Avoiding constipation is recommended because it reduces pressure on the prostate region; a fibre-rich diet and regular fluids help in this respect. While the catheter is in place, careful hygiene and catheter care as instructed are important for an uneventful recovery.
Although most patients pass through recovery comfortably, it is important to know which symptoms are expected and which require attention. Mild burning on urination, temporarily increased frequency and slight discolouration of the urine are anticipated. By contrast, inability to pass urine, high fever, severe pain or heavy bleeding should be assessed without delay. Explaining this distinction in advance allows patients to avoid unnecessary worry while still seeking care promptly when a genuine problem arises.
Follow-Up After Treatment
In prostate cancer care, structured follow-up after the procedure matters as much as the procedure itself. The purpose of follow-up after robotic HIFU is to confirm the effectiveness of treatment, to detect any recurrence early and to monitor the course of urinary and sexual function. The programme is planned individually, but a general framework applies.
The cornerstone of follow-up is regular PSA measurement. Blood tests are performed at set intervals after the procedure and the trend of the PSA value is tracked. With successful treatment, PSA falls and remains stable at a low level. If the value begins to rise significantly, further investigation follows — usually a surveillance MRI and, where indicated, targeted biopsies from the treated area.
Follow-up typically includes:
- PSA testing at closer intervals in the first year, then progressively less often in subsequent years.
- Surveillance prostate MRI at defined time points to image the treated zone.
- A confirmatory biopsy for histological assessment if a suspicious finding appears.
- Periodic review of urinary function, urine flow rate and sexual function.
Patients also have an active role during follow-up: certain symptoms should be observed and reported. Progressively increasing difficulty passing urine, recurrent urinary tract infections, persistent blood in the urine or a general decline in wellbeing should be brought to the physician's attention. Regular follow-up is an inseparable part of the treatment — both for judging its success and for allowing early intervention when needed. Even when the disease appears well controlled after robotic HIFU, adherence to the follow-up programme is decisive for long-term results. Patients who travel internationally for treatment can usually coordinate later blood tests and imaging with a physician near home, with the results reviewed by the treating team.
The structure of the programme usually evolves over time. The first year involves closer monitoring to confirm effectiveness and catch early problems; in later years, if the disease remains stable, the intervals lengthen — but surveillance is never abandoned altogether, because part of the prostate tissue remains in place and long-term monitoring retains its value. Keeping scheduled appointments is as important to the overall outcome as the treatment itself.
Follow-up covers quality of life as well as cancer control. Urinary function, flow rate and sexual function are reviewed at intervals, and supportive measures are arranged when problems arise in these areas. Follow-up thus becomes more than a search for recurrence: it is a holistic process attending to the patient's overall wellbeing — an approach fully in keeping with the tissue-preserving philosophy of robotic HIFU.
How Does It Compare with Other Treatment Options?
No single treatment is ideal for every man with prostate cancer; each approach has its own strengths and limitations. Considering robotic HIFU alongside the alternatives helps clarify which option may come to the fore in which situation.
Radical prostatectomy — surgical removal of the entire prostate — is a powerful option, particularly when the cancer is more extensive or more aggressive. The operation, however, can carry a higher risk of side effects such as urinary incontinence and loss of sexual function, and recovery takes longer. Robotic HIFU aims to reduce these risks by preserving tissue, but it is chosen only for suitable, limited disease.
Radiation therapy (radiotherapy) is likewise an effective treatment for prostate cancer and is frequently used in patients who do not wish to undergo surgery. It may require sessions spread over several weeks and can cause long-term bowel and urinary side effects in the surrounding tissue. HIFU, by contrast, is delivered in a single, precisely targeted session and can be repeated if needed.
Active surveillance refers to closely monitoring very low-risk, slow-growing cancers without immediate treatment. It is an appropriate choice for some patients, but if the disease progresses during surveillance, active treatment begins. Robotic HIFU can also be viewed as an intermediate step between active surveillance and major surgery.
The main factors weighed in the comparison are:
- The stage of the cancer, its aggressiveness and its extent within the prostate.
- The patient's age, general health and life expectancy.
- The priority placed on preserving urinary control and sexual function.
- The likelihood of needing further treatment in the future, and how much each option would restrict it.
In summary, for the right patient, robotic HIFU is positioned as a tissue-preserving option with rapid recovery that can be repeated when necessary. Each method has its own place, and the right choice emerges from assessing the characteristics of the disease together with the patient's priorities.
One dimension often overlooked in comparisons is how open each treatment leaves future options. After radical surgery, radiation remains available as a salvage option; conversely, surgery in a prostate that has received wide-field radiation is technically more demanding. A notable feature of robotic HIFU in this landscape is that it can be repeated and largely keeps subsequent treatment pathways open. This flexibility is a relevant consideration, particularly for younger patients with a long life expectancy.
Quality of life carries increasing weight in these comparisons. Because early-stage prostate cancer can follow a slow course, the quality of the years a patient lives after treatment matters greatly, and preservation of urinary control and sexual function are decisive elements of it. The tissue-preserving character of robotic HIFU can contribute to protecting these functions in suitable patients — with the caveat that this advantage applies only to appropriate, limited disease, and that advanced cases may require more comprehensive treatment.
Ultimately, no comparison establishes any one method as universally superior. Every cancer behaves differently, and every patient's priorities differ. In modern practice, the options are treated not as a contest but as a menu, and the most appropriate choice is usually made through joint assessment by several specialties. Within that menu, robotic HIFU takes its place as a balanced, tissue-preserving option for the suitable patient.
When Should You See a Doctor?
Early evaluation of prostate problems is important for the timely detection of both benign enlargement and cancer. Early-stage prostate cancer very often causes no symptoms at all, which is why men in the relevant age groups are advised not to wait for symptoms but to attend regular check-ups.
A urological evaluation is advisable in the following situations:
- Difficulty passing urine, a weakened stream, or interrupted flow.
- Waking frequently at night to urinate, and increased daytime frequency.
- Burning during urination or a sense of incomplete bladder emptying.
- Blood in the urine or semen.
- Unexplained bone pain in the lower back, hips or legs.
In addition, men with a family history of prostate cancer carry a higher risk and are well advised to begin check-ups earlier. Even in the absence of symptoms, PSA testing and examination from a certain age onwards can identify cancer while it is still silent. Early diagnosis is also what makes tissue-preserving, quick-recovery treatments such as robotic HIFU feasible, since these methods are most suitable for organ-confined, early-stage disease.
For men who have already been diagnosed with prostate cancer and are weighing their options, an early consultation is equally valuable. A comprehensive review of the MRI and biopsy findings establishes whether robotic HIFU is suitable and which approach makes the most sense. The healthiest path is a treatment decision made with accurate information — neither rushed nor unnecessarily delayed.
It should be remembered that most of these symptoms are not specific to prostate cancer. Difficulty urinating or increased frequency is very often due to non-cancerous causes such as benign prostatic enlargement. Because the symptoms can overlap with cancer, however, proper evaluation is all the more important. The aim is not to attribute every symptom to cancer, but to identify the true cause through appropriate investigation — an approach that both prevents unnecessary anxiety and ensures that genuinely significant conditions are not missed.
Early presentation has one further value: it preserves the breadth of treatment choices. When cancer is diagnosed while still confined to the organ, many options remain on the table, including tissue-preserving methods such as robotic HIFU. As disease advances, the options narrow and more extensive treatment may become necessary. Regular evaluation at the appropriate age, without waiting for symptoms, is therefore the most sensible course for both diagnosis and treatment flexibility.
Final Considerations
Robotic HIFU is a newer-generation approach to prostate cancer treatment built around the principle of tissue preservation. Without an incision and without radiation, it aims to target and destroy the cancerous region with millimetre-level precision using focused ultrasound energy alone. The structures critical for urinary control and sexual function are spared as far as possible, and recovery is markedly shorter and more comfortable than after open or laparoscopic surgery.
The method performs at its strongest in organ-confined, low- and intermediate-risk cancers that can be clearly delineated on MRI. Advanced, extensive or extraprostatic disease calls for more comprehensive treatment. Whether robotic HIFU is appropriate for a given patient is therefore determined by considering the MRI, biopsy and blood results together with the patient's overall condition and expectations.
One point deserves particular emphasis: regular follow-up after treatment is as decisive as the treatment itself. Surveillance through PSA monitoring, imaging and biopsy when indicated is essential both for confirming success and for catching any recurrence early. When careful patient selection, meticulous technique and structured follow-up come together, robotic HIFU offers a balanced option in prostate cancer care — one that attends to disease control and quality of life alike.
This content is provided for general information only and does not replace medical diagnosis, examination or treatment. Please consult a qualified specialist physician about your individual situation.
